Related Experiment Video
Updated: Jun 9, 2026
10:31
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Obesity and chronic kidney disease
1Los Angeles Biomedical Research Institute and Department of Medicine, Harbor-UCLA Medical Center, Torrance, California 90502, USA. jkopple@labiomed.org
Summary
Obesity significantly contributes to chronic kidney disease (CKD) development and progression through various mechanisms. More effective obesity treatments are needed to prevent and manage CKD associated with obesity.
Area of Science:
- Nephrology
- Metabolic Disorders
Background:
- Obesity is a prevalent condition linked to numerous health issues.
- Chronic kidney disease (CKD) is a significant global health concern.
- Obesity is increasingly recognized as a major risk factor for CKD development and progression.
Purpose of the Study:
- To elucidate the multifaceted roles of obesity in the pathogenesis of CKD.
- To highlight the mechanisms through which obesity adversely affects renal physiology and metabolism.
- To underscore the urgent need for improved obesity management strategies to combat CKD.
Main Methods:
- Review of existing literature on obesity and kidney disease.
- Analysis of pathophysiological pathways linking obesity to CKD.
- Identification of key metabolic and physiological alterations in obesity-related kidney dysfunction.
Main Results:
- Obesity predisposes individuals to diabetic nephropathy, hypertensive nephrosclerosis, and focal and segmental glomerulosclerosis.
- Obesity increases the risk of calcium oxalate and urate stones.
- Obesity is associated with heightened proteinuria and accelerated CKD progression.
- Obesity alters renal physiology and metabolism through complex mechanisms.
Conclusions:
- Obesity is a critical determinant in the development and advancement of CKD.
- Understanding the drivers of excessive energy intake and treatment resistance in obesity is crucial.
- Developing effective interventions for obesity is paramount for preventing and managing CKD.
Related Concept Videos
01:25Chronic Kidney Disease I: Introduction
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...